JPH07316077A - Composition for enteric coating - Google Patents

Composition for enteric coating

Info

Publication number
JPH07316077A
JPH07316077A JP13122994A JP13122994A JPH07316077A JP H07316077 A JPH07316077 A JP H07316077A JP 13122994 A JP13122994 A JP 13122994A JP 13122994 A JP13122994 A JP 13122994A JP H07316077 A JPH07316077 A JP H07316077A
Authority
JP
Japan
Prior art keywords
coating
composition
liquid
water
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP13122994A
Other languages
Japanese (ja)
Inventor
Hiroyuki Nishii
宏行 西井
Masatake Miura
正剛 三浦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to JP13122994A priority Critical patent/JPH07316077A/en
Publication of JPH07316077A publication Critical patent/JPH07316077A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PURPOSE:To obtain a composition for a water-soluble enteric coating useful as tablet, granule, etc., sufficiently satisfying resistance to gastric juice and decomposition in gastric juice, having excellent film-forming properties and workability, by adding a sucrose fatty acid ester, etc., to a specific water- dispersible copolymer. CONSTITUTION:This composition for a water-soluble enteric coating is obtained by blending (A) a water-dispersible copolymer prepared by subjecting ethyl acrylate and methacrylic acid to emulsion polymerization with (B) preferably 2-7wt.% (based on solid content of the component A) of a sucrose fatty acid ester (preferably 6-15 HLB) and (B) preferably 5-10wt.% of a polyethylene glycol, triethyl citrate, triacetin, polysorbate 80, castor oil, acetylated monoglyceride, glycerol or its mixture.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、錠剤、顆粒剤等の医薬
製剤に、腸溶性コーティングを施す際に良好な成膜性を
持ち、かつ作業性の良好な組成物に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition having good film-forming properties and good workability when an enteric coating is applied to pharmaceutical preparations such as tablets and granules.

【0002】[0002]

【従来の技術】医薬製剤の腸溶性コーティングに、アク
リル酸エチルとメタアクリル酸の乳化重合で得た水分散
性共重合体を用いることは公知である。この場合コーテ
ィング層のひび割れ、脆化を防ぐため、可塑剤の添加は
不可欠であり、ポリエチレングリコール、トリアセチ
ン、クエン酸トリエチル等が好適な可塑剤として従来用
いられてきた。また、これら可塑剤を用いた場合、コー
ティングの際粘着性が増大し、錠剤或いは顆粒同士が固
着し、団粒を形成するため、従来より付着防止のためタ
ルクが配合されていた。しかしながら、タルクは水中で
の分散安定性が悪く、コーティングの際、途中経路での
沈着或いはスプレーガンノズルのつまりを発生し、作業
性を著しく低下させる場合があった。一方、上記問題を
解決するものとして、アクリル酸エチルとメタアクリル
酸の乳化重合で得た水分散性の共重合体とショ糖脂肪酸
エステル及び水を主成分とする組成物がしられている
(特公平2−50885号公報)。
It is known to use water-dispersible copolymers obtained by emulsion polymerization of ethyl acrylate and methacrylic acid for enteric coating of pharmaceutical preparations. In this case, in order to prevent cracking and embrittlement of the coating layer, the addition of a plasticizer is indispensable, and polyethylene glycol, triacetin, triethyl citrate and the like have been conventionally used as suitable plasticizers. Further, when these plasticizers are used, the tackiness during coating increases, and the tablets or granules stick to each other to form aggregates, so that talc has been conventionally blended to prevent adhesion. However, talc has poor dispersion stability in water, and during coating, deposition in the intermediate path or clogging of the spray gun nozzle occurs, which may significantly reduce workability. On the other hand, as a solution to the above problem, there is a composition containing a water-dispersible copolymer obtained by emulsion polymerization of ethyl acrylate and methacrylic acid, a sucrose fatty acid ester, and water as main components ( Japanese Patent Publication No. 2-50885).

【0003】[0003]

【解決しようとする課題】しかしながら、上記組成物は
コーティングの際、成膜性が若干劣ることから均一なコ
ーティングを施すためには比較的多量の皮膜剤が必要で
あった。
However, since the composition described above is slightly inferior in film-forming property during coating, a relatively large amount of film-forming agent is required for uniform coating.

【0004】[0004]

【課題を解決するための手段】本発明者は前記問題点に
鑑み、成膜性が良好でかつ作業性の良好な腸溶性コーテ
ィング剤組成物について鋭意検討を進めた結果、ショ糖
脂肪酸エステルおよびポリエチレングリコール等の可塑
剤を併用することにより目的を達成できることを見いだ
し、本発明に到達した。すなわち、本発明はアクリル酸
エチルとメタアクリル酸の乳化重合で得られる水分散性
共重合体に、(i) ショ糖脂肪酸エステル及び、(ii)ポリ
エチレングリコール、クエン酸トリエチル、トリアセチ
ン、ポリソルベート80、ヒマシ油、アセチル化モノグリ
セリド、グリセリンまたはそれらの混合物を加えること
を特徴とする水性腸溶性コーティング用組成物に関する
ものである。
In view of the above problems, the present inventor has conducted earnest studies on an enteric coating agent composition having good film-forming property and good workability, and as a result, sucrose fatty acid ester and They have found that the object can be achieved by using a plasticizer such as polyethylene glycol in combination, and have reached the present invention. That is, the present invention is a water-dispersible copolymer obtained by emulsion polymerization of ethyl acrylate and methacrylic acid, (i) sucrose fatty acid ester and (ii) polyethylene glycol, triethyl citrate, triacetin, polysorbate 80, The present invention relates to an aqueous enteric coating composition, which is characterized by adding castor oil, acetylated monoglyceride, glycerin or a mixture thereof.

【0005】本発明において使用されるアクリル酸エチ
ルとメタアクリル酸の乳化重合で得られる水分散性共重
合体としては、1993年発行の医薬品添加物規格(厚
生省薬務局審査課監修)にメタアクリル酸コポリマー、
別名オイドラギッド(登録商標)L30D−55として収載
されているものが好適である。乳化重合では重合と乳化
が同時に行われ短時間に高重合度の樹脂が生成し、その
樹脂は極めて微粒子(0.01〜1μm)状で水中に高濃度
(〜65%)で、かつ安定に分散したエマルジョン状態で
得られる。ショ糖脂肪酸エステルとしてはラウリン酸、
ミリスチン酸、パルミチン酸、ステアリン酸、オレイン
酸、リノール酸などの高級脂肪酸のエステル或いは牛
脂、ラノリン、ヤシ油、ヒマシ油、サンフラワー油及び
それらの硬化油などの混合脂肪酸のエステル等がありH
LB6〜15のものが好ましい。ショ糖脂肪酸エステルの
使用量は前記共重合体の固形分に対して1〜15重量%
が適当であり、特に好ましくは2〜7重量%である。
The water-dispersible copolymer obtained by emulsion polymerization of ethyl acrylate and methacrylic acid used in the present invention is defined as a metabolite according to the Pharmaceutical Additives Standard (supervised by the Examination Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare) issued in 1993. Acrylic acid copolymer,
Those listed as alias Eudragit (registered trademark) L30D-55 are preferable. In emulsion polymerization, polymerization and emulsification are performed at the same time, and a resin having a high degree of polymerization is produced in a short time. Obtained as an emulsion. Lauric acid as sucrose fatty acid ester,
There are esters of higher fatty acids such as myristic acid, palmitic acid, stearic acid, oleic acid and linoleic acid, or esters of mixed fatty acids such as beef tallow, lanolin, coconut oil, castor oil, sunflower oil and their hardened oils.
Those having LB6 to 15 are preferable. The amount of sucrose fatty acid ester used is 1 to 15% by weight based on the solid content of the copolymer.
Is suitable, and particularly preferably 2 to 7% by weight.

【0006】また本発明において使用される可塑剤、す
なわちポリエチレングリコール、クエン酸トリエチル、
トリアセチン、ポリソルベート80、ヒマシ油、アセチル
化モノグリセリド、グリセリンまたはこれらの混合物の
使用量は前記共重合体の固形分に対して1〜15重量%
が適当であり、特に好ましくは5〜10重量%である。
本組成物の調製方法としては精製水にショ糖脂肪酸エス
テル及び可塑剤を溶解または分散し、これにアクリル酸
エチルとメタアクリル酸の乳化重合で得られる水分散性
共重合体を添加混合する方法、或いは該共重合体にショ
糖脂肪酸エステル及び可塑剤を溶解または分散し、必要
に応じて水で希釈する方法等があるが、要はショ糖脂肪
酸エステル、可塑剤、該共重合体及び必要に応じて水を
組成物全量の所定の割合で均一に含まれるように調製す
ればよく上記方法に限定されるものではない。
The plasticizers used in the present invention, namely polyethylene glycol, triethyl citrate,
The use amount of triacetin, polysorbate 80, castor oil, acetylated monoglyceride, glycerin or a mixture thereof is 1 to 15% by weight based on the solid content of the copolymer.
Is suitable, and particularly preferably 5 to 10% by weight.
As a method for preparing the composition, a method of dissolving or dispersing a sucrose fatty acid ester and a plasticizer in purified water, and adding and mixing a water-dispersible copolymer obtained by emulsion polymerization of ethyl acrylate and methacrylic acid Alternatively, there is a method of dissolving or dispersing a sucrose fatty acid ester and a plasticizer in the copolymer, and diluting with water as necessary, but the point is that the sucrose fatty acid ester, the plasticizer, the copolymer and the necessary The water may be prepared so as to be uniformly contained in a predetermined proportion of the total amount of the composition according to the above, and the method is not limited to the above method.

【0007】本発明の組成物には、必要に応じて着色
料、香料、顔料等の助剤を本発明の目的に影響を与えな
い程度に添加することもできる。本発明の組成物を用い
て固形製剤をコーティングする方法としては従来公知の
コーティング装置例えばパンコーティング装置、流動層
コーティング装置、遠心流動コーティング装置、複合型
流動コーティング装置、ドラムタイプコーティング装置
等を用いて、該組成物を固形製剤上にスプレーコーティ
ングする方法が採用できる。使用される固形製剤として
は特に制限はない。
If necessary, auxiliary agents such as colorants, fragrances and pigments may be added to the composition of the present invention to such an extent that the object of the present invention is not affected. As a method for coating a solid preparation with the composition of the present invention, a conventionally known coating device such as a pan coating device, a fluidized bed coating device, a centrifugal fluidized coating device, a composite fluidized coating device, a drum type coating device, etc. is used. A method of spray coating the composition on a solid preparation can be adopted. The solid preparation used is not particularly limited.

【0008】[0008]

【発明の効果】本発明の組成物を用いることにより、従
来用いられている腸溶性コーティング剤組成物の問題点
が解消される。例えば、可塑剤のみの添加において生じ
る錠剤または顆粒同士の固着、またはタルクを添加した
際のスプレーノズル、液送経路の詰まりが回避でき、そ
の上ショ糖脂肪酸エステルのみの添加によるものに比
べ、さらに良好な成膜性が得られ、コーティング中の良
好な作業性、胃液に対する良好な抵抗性、腸液中での良
好な崩壊性のいずれも充分に満足する腸溶性製剤が得ら
れる。
EFFECTS OF THE INVENTION By using the composition of the present invention, the problems of conventionally used enteric coating composition can be solved. For example, it is possible to avoid sticking of tablets or granules caused by addition of a plasticizer only, or spray nozzle when talc is added, clogging of the liquid feeding route, and moreover, compared with the addition of only sucrose fatty acid ester, A good film-forming property can be obtained, and an enteric coated preparation can be obtained which is sufficiently satisfied with good workability during coating, good resistance to gastric juice, and good disintegration in intestinal juice.

【0009】[0009]

【実施例】次に実施例を挙げて本発明を具体的に説明す
るが、本発明はこれによって何ら限定されるものではな
い。
EXAMPLES The present invention will now be specifically described with reference to examples, but the present invention is not limited thereto.

【0010】実施例 1 (コーティング液組成) オイドラギッド(登録商標)L30D−55(ロームファーマ社製) (固形分30%の分散液) 50部 ショ糖脂肪酸エステル(DKエステル(登録商標)F−50) (第一工業製薬) 0.9部 ポリエチレングリコール6000 0.9部 精製水 48.2部 (コーティング)白糖・デンプン混合顆粒1Kgに上記コ
ーティング液を1.2Kgスプレーコーティングした。コー
ティング操作中顆粒のくっつきも見られず平滑な被覆表
面の顆粒が得られた。得られた製剤の第12改正日本薬局
方一般試験法第43崩壊試験法の結果は下記の通りであっ
た。 第1液及び第2液に対する崩壊性 第1液(pH1.2 )・・・ 崩壊せず(1時間) 第2液(pH6.8 )・・・ 5〜10分で崩壊
Example 1 (Composition of coating liquid) Eudragit (registered trademark) L30D-55 (manufactured by Rohm Pharma) (dispersion liquid having a solid content of 30%) 50 parts Sucrose fatty acid ester (DK ester (registered trademark) F-50) ) (Daiichi Kogyo Seiyaku Co., Ltd.) 0.9 part Polyethylene glycol 6000 0.9 part Purified water 48.2 parts (Coating) 1 kg of sucrose / starch mixed granules was spray-coated with 1.2 kg of the above coating liquid. No sticking of the granules was observed during the coating operation, and granules having a smooth coated surface were obtained. The results of the 12th revised Japanese Pharmacopoeia general test method 43rd disintegration test method of the obtained preparation were as follows. Disintegration with 1st liquid and 2nd liquid 1st liquid (pH1.2) ・ ・ ・ No disintegration (1 hour) 2nd liquid (pH6.8) ・ ・ ・ Disintegration in 5-10 minutes

【0011】実施例 2 (コーティング液組成) オイドラギッド(登録商標)L30D−55(ロームファーマ社製) (固形分30%の分散液) 50部 ショ糖脂肪酸エステル(DKエステルF−50(登録商標)) (第一工業製薬) 0.9部 クエン酸トリエチル 0.9部 精製水 48.2部 (コーティング)上記組成のコーティング液を用いて実
施例1の場合と同一条件でコーティングを施した。コー
ティング操作中の顆粒のくっつきも見られず平滑な顆粒
表面が得られた。得られた製剤の第12改正日本薬局方一
般試験法第43崩壊試験法の結果は下記の通りであった。 第1液及び第2液に対する崩壊性 第1液(pH1.2 )・・・ 崩壊せず(1時間) 第2液(pH6.8 )・・・ 5〜10分で崩壊
Example 2 (Coating liquid composition) Eudragit (registered trademark) L30D-55 (manufactured by Rohm Pharma) (dispersion liquid having a solid content of 30%) 50 parts Sucrose fatty acid ester (DK ester F-50 (registered trademark)) (Daiichi Kogyo Seiyaku Co., Ltd.) 0.9 part Triethyl citrate 0.9 part Purified water 48.2 parts (Coating) Coating was performed under the same conditions as in Example 1 using the coating solution having the above composition. No sticking of the granules was observed during the coating operation, and smooth granule surfaces were obtained. The results of the 12th revised Japanese Pharmacopoeia general test method 43rd disintegration test method of the obtained preparation were as follows. Disintegration with 1st liquid and 2nd liquid 1st liquid (pH1.2) ・ ・ ・ No disintegration (1 hour) 2nd liquid (pH6.8) ・ ・ ・ Disintegration in 5-10 minutes

【0012】実施例 3 (コーティング液組成) オイドラギッド(登録商標)L30D−55(ロームファーマ社製) (固形分30%の分散液) 50部 ショ糖脂肪酸エステル(DKエステルF−50(登録商標)) 0.45部 クエン酸トリエチル 1.35部 精製水 48.2部 (コーティング)上記組成のコーティング液を用いて実
施例1の場合と同一条件でコーティングを施した。コー
ティング操作中の顆粒のくっつきも見られず平滑な顆粒
表面が得られた。得られた製剤の第12改正日本薬局方一
般試験法第43崩壊試験法の結果は下記の通りであった。 第1液及び第2液に対する崩壊性 第1液(pH1.2 )・・・ 崩壊せず(1時間) 第2液(pH6.8 )・・・ 5〜10分で崩壊
Example 3 (Composition of coating liquid) Eudragit (registered trademark) L30D-55 (manufactured by Rohm Pharma) (dispersion liquid having a solid content of 30%) 50 parts Sucrose fatty acid ester (DK ester F-50 (registered trademark)) ) 0.45 parts Triethyl citrate 1.35 parts Purified water 48.2 parts (Coating) Coating was performed under the same conditions as in Example 1 using the coating solution having the above composition. No sticking of the granules was observed during the coating operation, and smooth granule surfaces were obtained. The results of the 12th revised Japanese Pharmacopoeia general test method 43rd disintegration test method of the obtained preparation were as follows. Disintegration with 1st liquid and 2nd liquid 1st liquid (pH1.2) ・ ・ ・ No disintegration (1 hour) 2nd liquid (pH6.8) ・ ・ ・ Disintegration in 5-10 minutes

【0013】実施例 4 (コーティング液組成) オイドラギッド(登録商標)L30D−55(ロームファーマ社製) (固形分30%の分散液) 50部 ショ糖脂肪酸エステル(DKエステルF−50(登録商標)) (第一工業製薬) 1.08部 クエン酸トリエチル 0.72部 精製水 48.2部 (コーティング)上記組成のコーティング液を用いて実
施例1の場合と同一条件でコーティングを施した。コー
ティング操作中の顆粒のくっつきも見られず平滑な顆粒
表面が得られた。得られた製剤の第12改正日本薬局方一
般試験法第43崩壊試験法の結果は下記の通りであった。 第1液及び第2液に対する崩壊性 第1液(pH1.2 )・・・ 崩壊せず(1時間) 第2液(pH6.8 )・・・ 5〜10分で崩壊
Example 4 (Coating liquid composition) Eudragit (registered trademark) L30D-55 (manufactured by Rohm Pharma) (dispersion liquid having a solid content of 30%) 50 parts Sucrose fatty acid ester (DK ester F-50 (registered trademark)) (Daiichi Kogyo Seiyaku Co., Ltd.) 1.08 parts Triethyl citrate 0.72 parts Purified water 48.2 parts (Coating) Coating was performed under the same conditions as in Example 1 using the coating liquid having the above composition. No sticking of the granules was observed during the coating operation, and smooth granule surfaces were obtained. The results of the 12th revised Japanese Pharmacopoeia general test method 43rd disintegration test method of the obtained preparation were as follows. Disintegration with 1st liquid and 2nd liquid 1st liquid (pH1.2) ・ ・ ・ No disintegration (1 hour) 2nd liquid (pH6.8) ・ ・ ・ Disintegration in 5-10 minutes

【0014】対照例 1 (コーティング液組成) オイドラギッド(登録商標)L30D−55(ロームファーマ社製) (固形分30%の分散液) 50部 ショ糖脂肪酸エステル(DKエステル(登録商標)F−50) (第一工業製薬) 1.8部 精製水 48.2部 (コーティング)上記組成のコーティング液を用いて実
施例1の場合と同一条件でコーティングを施した。コー
ティング操作中の顆粒のくっつきも見られず平滑な顆粒
表面が得られた。得られた製剤の第12改正日本薬局方一
般試験法第43崩壊試験法の結果は下記の通りであった。 第1液及び第2液に対する崩壊性 第1液(pH1.2 )・・・ 液が若干白濁(1時間) 第2液(pH6.8 )・・・ 5〜10分で崩壊
Control Example 1 (Coating liquid composition) Eudragit (registered trademark) L30D-55 (manufactured by Rohm Pharma) (dispersion liquid having a solid content of 30%) 50 parts Sucrose fatty acid ester (DK ester (registered trademark) F-50) (Daiichi Kogyo Seiyaku Co., Ltd.) 1.8 parts Purified water 48.2 parts (Coating) Coating was performed under the same conditions as in Example 1 using the coating liquid having the above composition. No sticking of the granules was observed during the coating operation, and smooth granule surfaces were obtained. The results of the 12th revised Japanese Pharmacopoeia general test method 43rd disintegration test method of the obtained preparation were as follows. Disintegration with 1st liquid and 2nd liquid 1st liquid (pH1.2) ・ ・ ・ Liquid is slightly cloudy (1 hour) 2nd liquid (pH6.8) ・ ・ ・ Disintegration in 5-10 minutes

【0015】対照例 2 (コーティング液組成) オイドラギッド(登録商標)L30D−55(ロームファーマ社製) (固形分30%の分散液) 50部 ポリエチレングリコール6000 1.8部 精製水 48.2部 (コーティング)上記組成のコーティング液を用いて実
施例1の場合と同一条件でコーティングを施した。コー
ティング操作中、顆粒のくっつきが顕著で、団粒が発生
した。顆粒表面は平滑であった。得られた製剤の第12改
正日本薬局方一般試験法第43崩壊試験法の結果は下記の
通りであった。 第1液及び第2液に対する崩壊性 第1液(pH1.2 )・・・ 崩壊せず(1時間) 第2液(pH6.8 )・・・ 5〜10分で崩壊
Control Example 2 (Coating liquid composition) Eudragit (registered trademark) L30D-55 (manufactured by Rohm Pharma) (dispersion liquid having a solid content of 30%) 50 parts Polyethylene glycol 6000 1.8 parts Purified water 48.2 parts (coating) The above composition Coating was performed under the same conditions as in Example 1 using the coating liquid of 1. During the coating operation, the sticking of the granules was remarkable and aggregates were generated. The granule surface was smooth. The results of the 12th revised Japanese Pharmacopoeia general test method 43rd disintegration test method of the obtained preparation were as follows. Disintegration with 1st liquid and 2nd liquid 1st liquid (pH1.2) ・ ・ ・ No disintegration (1 hour) 2nd liquid (pH6.8) ・ ・ ・ Disintegration in 5-10 minutes

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】アクリル酸エチルとメタアクリル酸の乳化
重合で得られる水分散性共重合体に、(i) ショ糖脂肪酸
エステル及び、(ii)ポリエチレングリコール、クエン酸
トリエチル、トリアセチン、ポリソルベート80、ヒマシ
油、アセチル化モノグリセリド、グリセリンまたはそれ
らの混合物を加えることを特徴とする水性腸溶性コーテ
ィング用組成物。
1. A water-dispersible copolymer obtained by emulsion polymerization of ethyl acrylate and methacrylic acid, wherein (i) sucrose fatty acid ester and (ii) polyethylene glycol, triethyl citrate, triacetin, polysorbate 80, An aqueous enteric coating composition, characterized in that castor oil, acetylated monoglyceride, glycerin or a mixture thereof is added.
JP13122994A 1994-05-20 1994-05-20 Composition for enteric coating Pending JPH07316077A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13122994A JPH07316077A (en) 1994-05-20 1994-05-20 Composition for enteric coating

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13122994A JPH07316077A (en) 1994-05-20 1994-05-20 Composition for enteric coating

Publications (1)

Publication Number Publication Date
JPH07316077A true JPH07316077A (en) 1995-12-05

Family

ID=15053048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13122994A Pending JPH07316077A (en) 1994-05-20 1994-05-20 Composition for enteric coating

Country Status (1)

Country Link
JP (1) JPH07316077A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100469943B1 (en) * 2002-03-20 2005-02-02 삼성정밀화학 주식회사 A method for preparing acryl copolymer used for enteric coating agent
JP2006508960A (en) * 2002-11-14 2006-03-16 シントン・ベスローテン・フェンノートシャップ Pharmaceutical pellets containing tamsulosin and method for producing the same
JP2020002012A (en) * 2018-06-25 2020-01-09 日本酢ビ・ポバール株式会社 Coating composition as well as oral solid preparation and method for producing the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100469943B1 (en) * 2002-03-20 2005-02-02 삼성정밀화학 주식회사 A method for preparing acryl copolymer used for enteric coating agent
JP2006508960A (en) * 2002-11-14 2006-03-16 シントン・ベスローテン・フェンノートシャップ Pharmaceutical pellets containing tamsulosin and method for producing the same
JP2020002012A (en) * 2018-06-25 2020-01-09 日本酢ビ・ポバール株式会社 Coating composition as well as oral solid preparation and method for producing the same

Similar Documents

Publication Publication Date Title
EP0152038B1 (en) Coating for pharmaceutical compositions
DE69630215T2 (en) DILTIAZEM FORMULATION WITH CONTROLLED RELEASE
US5478573A (en) Delayed, sustained-release propranolol pharmaceutical preparation
EP0704208B1 (en) Coating and binder compositions for pharmaceutical forms and pharmaceutical forms prepared therewith
DE69732983T2 (en) PREPARATION WITH EXTENDED RELEASE USING A THERMAL CONVERSION AND METHOD FOR THE PRODUCTION THEREOF
EP2046305A2 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
IE850307L (en) Diffusion-coated multiple-units dosage form
AU2005231145A1 (en) Enteric coatings for orally ingestible substrates
WO2003080032A2 (en) Pharmaceutical formulation for the active ingredient budesonide
CN105916598A (en) Immediate release film coatings containing medium chain glycerides and substrates coated therewith
JPH07316077A (en) Composition for enteric coating
JPH02240016A (en) Water dispensing gemfibrozyl composition
JP3471977B2 (en) Enteric preparations coated with solvent-free enteric coatings using liquid plasticizers
EP0403959B1 (en) Film forming aqueous coating preparation for solid pharmaceuticals, its production and use
JPH0138091B2 (en)
JPH08333238A (en) Enteric coated preparation coated by solventless enteric coating agent using liquid wax
JP2001112421A (en) Water-soluble coating composition for food
JP2003093000A (en) Enteric coat for food, enteric food and method for producing the same
CA3093120A1 (en) Acidifying coatings and disintegration-resistant substrates coated therewith
CN101472569A (en) A pharmaceutical composition for the oral administration of omega polyenoic fatty acids
JPH0559098B2 (en)
US5358723A (en) Process and composition for the development of controlled release gemfibrozil dosage form
US20080033059A1 (en) Enteric Coating Compositions
JPH01113322A (en) Acrylic emulsion and ph-independent slowly releasing drug
JPS587607B2 (en) Method for manufacturing enteric-coated preparations